General MedicationsTOPICALStandard
HYFTOR
SIROLIMUS
Standard Dose
0.2%
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview HYFTOR is listed in Drugs@FDA under application 213478 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient SIROLIMUS Form and strength GEL;TOPICAL - 0.2% Sponsor NOBELPHARMA Submission history Latest submission status date: 2022-03-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview HYFTOR is listed in Drugs@FDA under application 213478 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient SIROLIMUS Form and strength GEL;TOPICAL - 0.2% Sponsor NOBELPHARMA Submission history Latest submission status date: 2022-03-22 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.